I am long on CLDX and Gale. I don't think you truly understand the impact and potential based on the news from the CLDX 1127 Phase 1. This drug can be a game changer with multiple indications and combinations treatments. The results of the phase 1 where not only met but exceeded. Safe and effective. Possible CURE. I would not discount this info. I love GALE as well. Completely undervalued.
Why not diversify your risk and invest in both GALE & CLDX as they both appear to be well managed companies with good products in development? That way if one company has issues with test failure, competition, product pricing, sales force, etc. it is less likely both will fail. If they are both successful, which I believe they will be, then it's a double win ........ they both seem to have significant market potential.
FYI - I've been long CLDX since 2008 and recently went long GALE. Good luck to longs of both GALE & CLDX.